Back

Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in diabetic patients with a higher impact on women

3 April 2025 (08:00 - 19:00)
Organised by: Logo
Congress Presentation Part of: Protecting the female heart life-long Cardiovascular Disease in Women EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

3 More presentations in this session

Presentation thumbnail
Gender differences in prevalence and management of hypertension in Switzerland from 1997 to 2022
Doctor S. Yi (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Evaluation of the age-related prevalence of cardiovascular risk factors to guide systematic long-term follow-up after preeclampsia
Mrs G. Jansen (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Earlier menopause is related to adverse left ventricular morphology and function in the UK Biobank
Doctor J. Marino (Greifswald, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Protecting the female heart life-long

The Event

Event poster

ESC Preventive Cardiology 2025

3 April - 5 April 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular outcomes in diabetic patients treated with SGLT2i and GLP1-RA: systematic review and meta-analysis
thumbnail
Congress Presentation
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry
thumbnail
Congress Presentation
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources